Increase of octanoate concentrations during extracorporeal albumin dialysis treatments

Therapeutic Apheresis and Dialysis

Volumn 13, Issue 5, 2009, Pages 437-443

  Klammt, Sebastian ^a   Koball, Sebastian ^a   Hickstein, Heiko ^a   Gloger, Martin ^a   Henschel, Joerg ^a   Mitzner, Steffen ^a   Stange, Jan ^a   Reisinger, Emil C ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Albumin Binding; Albumin Dialysis; Liver Failure; Octanoate; Stabilizer

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; OCTANOIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN DIALYSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD FILTER; BLOOD FLOW; BLOOD SAMPLING; CASE REPORT; DIALYSATE; DISEASE EXACERBATION; FATTY ACID BLOOD LEVEL; FEMALE; HEMOCONCENTRATION; HEPATIC ENCEPHALOPATHY; HUMAN; KIDNEY FUNCTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

DIALYSIS; DIALYSIS SOLUTIONS; EXTRACORPOREAL CIRCULATION; FEMALE; HEPATITIS, ALCOHOLIC; HEPATORENAL SYNDROME; HUMANS; LIVER FAILURE; MIDDLE AGED; OCTANOIC ACIDS; SERUM ALBUMIN; TIME FACTORS;

EID: 70349782443     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00763.x     Document Type: Article

References (35)

1. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club. Gut 2007 56 : 1310 1318.
2. Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. New Engl J Med 1999 341 : 403 409.
3. Gines A, Fernandez-Esparrach G, Monescillo A et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996 111 : 1002 1010.
4. Yu MW, Finlayson JS. Stabilization of human albumin by caprylate and acetyltryptophanate. Vox Sang 1984 47 : 28 40.
5. Anraku M, Kouno Y, Kai T, Tsurusaki Y, Yamasaki K, Otagiri M. The role of N-acetyl-methioninate as a new stabilizer for albumin products. Int J Pharm 2007 329 : 19 24.
6. Anraku M, Tsurusaki Y, Watanabe H, Maruyama T, Kragh-Hansen U, Otagiri M. Stabilizing mechanisms in commercial albumin preparations: octanoate and N-acetyl-L-tryptophanate protect human serum albumin against heat and oxidative stress. Biochim Biophys Acta 2004 1702 : 9 17.
7. Peters T. All About Albumin: Biochemistry, Genetics, and Medical Applications. San Diego : Academic Press, 1996.
8. Olsen H, Andersen A, Nordbo A, Kongsgaard UE, Bormer OP. Pharmaceutical-grade albumin: impaired drug-binding capacity in vitro. BMC Clin Pharmacol 2004 4 : 4.
9. Kragh-Hansen U. Structure and ligand binding properties of human serum albumin. Dan Med Bull 1990 37 : 57 84.
10. Noctor TA, Wainer IW, Hage DS. Allosteric and competitive displacement of drugs from human serum albumin by octanoic acid, as revealed by high-performance liquid affinity chromatography, on a human serum albumin-based stationary phase. J Chromatogr 1992 577 : 305 315.
11. Chuang VT, Otagiri M. How do fatty acids cause allosteric binding of drugs to human serum albumin? Pharm Res 2002 19 : 1458 1464.
12. Reine PA, Kongsgaard UE, Andersen A, Thogersen AK, Olsen H. Infusion of albumin attenuates changes in serum protein binding of drugs in surgical patients compared with volume replacement with HAES. Acta Anaesthesiol Scand 2008 52 : 406 412.
13. Kragh-Hansen U. Octanoate binding to the indole - and benzodiazepine binding region of human serum albumin. Biochem J 1991 273 : 641 644.
14. Rabinowitz JL, Staeffen J, Aumonier P et al. A method for serum octanoate in hepatic cirrhosis and hepatic encephalopathy. Clin Chem 1977 23 : 2202 2206.
15. Vici CD, Bachmann C, Gradwoht M, Colombo JP. Determination of medium chain fatty acids in serum. Clin Chim Acta 1988 172 : 233 238.
16. Yamamura N, Magata Y, Kitano H, Konishi J, Saji H. Evaluation of [1-11C]octanoate as a new radiopharmaceutical for assessing liver function using positron emission tomography. Nucl Med Biol 1998 25 : 467 472.
17. Rabinowitz JL, Staeffen J, Aumonier P et al. The effects of intravenous sodium octanoate on the rhesus monkey. Am J Gastroenterol 1978 69 : 187 190.
18. Druml W, Fischer M, Pidlich J, Lenz K. Fat elimination in chronic hepatic failure: long chain vs medium chain triglycerides. Am J Clin Nutr 1995 61 : 812 817.
19. van de Casteele M, Luypaerts A, Geypens B, Fevery J, Ghoos Y, Nevens F. Oxidative breakdown of octanoic acid is maintained in patients with cirrhosis despite advanced disease. Neurogastroenterol Motil 2003 15 : 113 120.
20. Smit JJ, Bosman DK, Jorning GG, de Haan JG, Maas MA, Chamuleau RA. The relationship between plasma free fatty acids and experimentally induced hepatic encephalopathy in the rat. Clin Chim Acta 1991 197 : 95 104.
21. Moroni F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmacol 1999 375 : 87 100.
22. Zieve L. Pathogenesis of hepatic encephalopathy. Metab Brain Dis 1987 2 : 147 165.
23. Zieve L, Shekleton M, Lyftogt C, Draves K. Ammonia, octanoate and a mercaptan depress regeneration of normal rat liver after partial hepatectomy. Hepatology 1985 5 : 28 31.
24. Zieve L, Lyftogt C, Draves K. Toxicity of a fatty acid and ammonia: interactions with hypoglycemia and Krebs cycle inhibition. J Lab Clin Med 1983 101 : 930 939.
25. Zieve FJ, Zieve L, Doizaki WM, Gilsdorf RB. Synergism between ammonia and fatty acids in the production of coma: implications for hepatic coma. J Pharmacol Exp Ther 1974 191 : 10 16.
26. Baraldi M, Zeneroli ML, Ventura E, Vezzelli C. An increase in cerebral benzodiazepine receptors induced by a subacute administration of ammonia, mercaptans and short-chain fatty acids in rats. Clin Sci (Lond) 1987 73 : 669 671.
27. Seige M, Kreymann B, Jeschke B, Schweigart U, Kopp KF, Classen M. Long-term treatment of patients with acute exacerbation of chronic liver failure by albumin dialysis. Transplant Proc 1999 31 : 1371 1375.
28. Sauer IM, Goetz M, Steffen I et al. In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD). Hepatology 2004 39 : 1408 1414.
29. Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. ASAIO J 1993 39 : 621 625.
30. Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R, Noldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001 12 : S75 S82.
31. Hassanein TI, Tofteng F, Brown RS Jr. et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007 46 : 1853 1862.
32. Heemann U, Treichel U, Loock J et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002 36 : 946 958.
33. Brunner E, Domhof S, Langer F. Nonparametric Analysis of Longitudinal Data in Factorial Experiments, 1st edn. New York : John Wiley Sons Inc, 2002.
34. Sen S, Jalan R, Williams R. Liver failure: basis of benefit of therapy with the molecular adsorbents recirculating system. Int J Biochem Cell Biol 2003 35 : 1306 1311.
35. Stange J, Mitzner S. A carrier mediated transport of toxins in a hybrid membrane. Int J Artif Organs 1996 19 : 677 691.